Armistice Capital, LLC has filed its 13F form on May 15, 2025 for Q1 2025 where it was disclosed a total value porftolio of $6.56 Billion distributed in 230 stocks.

Among their holdings, we can observe that their the top five positions include companies like: Ptc Therapeutics, Inc. with a value of $277M, Supernus Pharmaceuticals, Inc. with a value of $170M, Travere Therapeutics, Inc. with a value of $159M, Immunovant, Inc. with a value of $124M, and Neurocrine Biosciences Inc with a value of $111M.

Examining the 13F form we can see an decrease of $518M in the current position value, from $7.08B to 6.56B.

Armistice Capital, LLC is based out at New York, NY

Below you can find more details about Armistice Capital, LLC portfolio as well as his latest detailed transactions.

Portfolio value $6.56 Billion
ETFs: $2.71 Billion
Healthcare: $2.54 Billion
Consumer Cyclical: $435 Million
Technology: $368 Million
Consumer Defensive: $365 Million
Communication Services: $53.2 Million
Basic Materials: $45.8 Million
Industrials: $34.8 Million
Other: $16.3 Million

Stock Holdings Table

Stock Market Cap. Holding Value (Reported) # of Shares. Last Trade Trade History

Summary

  • Portfolio
  • No. of Stocks 230
  • Current Value $6.56 Billion
  • Prior Value $7.08 Billion
  • Filing
  • Period Q1 2025
  • Filing Date May 15, 2025
  • Form Type 13F-HR
  • Activity in Q1 2025
  • New Purchases 65 stocks
  • Additional Purchases 73 stocks
  • Sold out of 0 stocks
  • Reduced holdings in 60 stocks
Track This Portfolio

Track Armistice Capital, LLC Portfolio

Follow Armistice Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Armistice Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Armistice Capital, LLC with notifications on news.